RESEARCH USE ONLY. UK DISPATCH. ≥98% PURITY. SAME DAY DISPATCH BEFORE 2 PM MON–FRI. NOT FOR HUMAN CONSUMPTION
Lynx Peptides
Basket 0

Human phase 2 evidence

GLP-3 RT research overview

Review the published research context, areas studied and evidence limitations associated with this catalogue material.

Evidence context statedSources linkedLast reviewed

Research context

Published phase 2 research has examined retatrutide as a triple hormone-receptor agonist, including receptor-linked metabolic, body-mass and safety endpoints in adults.

Areas studied

  • GLP-1 receptor agonism
  • GIP receptor agonism
  • Glucagon receptor agonism
  • Metabolic and safety endpoints

Limitations and investigational status

Retatrutide remains an investigational compound, and the cited evidence is from a sponsor-funded phase 2 trial in a selected population. This does not establish approval, availability or suitability for human use.

References

  1. 1Jastreboff et al. - New England Journal of Medicine, 2023

For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.